The short answer
Hviid and colleagues examined periconceptional GLP-1 receptor agonist exposure and obstetric outcomes across Danish health registries from October 2009 to December 2023, published in Human Reproduction Open in 2026. Preterm birth risk was raised where the medicines were used for diabetes but not for weight management.
Key facts
- Study
- Hviid 2026 (PMID 41852577)
- Journal
- Hum Reprod Open
- Design
- Nationwide observational cohort
- Data source
- Danish health registries
- Period
- October 2009 - December 2023
- Liraglutide, diabetes
- Preterm birth aOR 1.70 (1.17-2.48)
- Semaglutide, diabetes
- Preterm birth aOR 1.84 (1.24-2.7)
- Weight management
- Association not seen
Why Danish registries suit this question
They link prescribing, diagnoses and outcomes across an entire population with very little loss to follow-up. Pregnancy outcomes in people exposed to a specific medicine around conception is a question requiring both completeness and scale, and no trial would ever be conducted to answer it. Exposure in pregnancy is not something anyone randomises.
What was found
Increased preterm birth risk among those using the medicines for diabetes: liraglutide adjusted odds ratio 1.70 with a 95% confidence interval of 1.17 to 2.48, and semaglutide 1.84 with an interval of 1.24 to 2.7. Among those using them for weight management, the association was not present.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the split is the actual result
Same medicines, same registry, same outcome, same period. The distinguishing feature between the two groups is the condition that prompted prescribing. A drug effect should not depend on why the drug was given, so the pattern points to the underlying diabetes rather than the medication, which the authors state as their own interpretation.
Why diabetes is a plausible cause here
Diabetes in pregnancy is an established risk factor for preterm birth through mechanisms long documented and independent of any modern medicine. An association appearing only where diabetes is present is consistent with the condition doing what it has always been known to do.
What the background section establishes about scale
The paper notes these agents are rapidly expanding among reproductive-age women, that they are not approved for use in pregnancy, and that inadvertent periconceptional exposure occurs frequently. It also notes that small studies have suggested no increased risk of major congenital malformations while comprehensive obstetric outcome data remained lacking. That is the gap this study addresses.
The limits
It is observational. Confounding by indication is what the design illuminates rather than something it wholly escapes, and residual confounding within each indication group remains possible. It reports obstetric outcomes rather than long-term outcomes for children, which is a separate question requiring longer follow-up.
The boundary
These are licensed medicines, not approved for use in pregnancy, prescribed and monitored clinically. Nothing supplied on this site is any of them, and nothing here is advice. Reproductive decisions belong with a clinician.
Frequently asked questions
Did the study find GLP-1 drugs cause preterm birth?
No. Raised risk appeared only where the medicines were used for diabetes, not for weight management, pointing to the underlying condition rather than the drug.
Why does the indication split matter so much?
A drug effect should not depend on why the drug was prescribed. That it did is evidence the association tracks the diabetes.
What are the study's limits?
It is observational, residual confounding within groups remains possible, and it reports obstetric outcomes rather than longer-term outcomes for children.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedHviid KVR et al., Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. Hum Reprod Open 2026 (PMID 41852577)pubmed.ncbi.nlm.nih.gov
- PubMedSaad Alfaiz A et al., GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety. Ann Med Surg 2025 (PMID 41377305)pubmed.ncbi.nlm.nih.gov
- PubMedSalamun V et al. Eur J Endocrinol 2018 (PMID 29703793)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Canada in January, India in MarchCanada became the first G7 nation where semaglutide patents expired, on 4 January 2026. India followed in March, with generics reported at 70-90% discounts.
- Two Pathways, Two TimescalesA generic drug shows bioequivalence. A biosimilar shows no clinically meaningful difference. The 40-residue line decides which applies.
- Comparing an Operation With an InjectionA 2026 network meta-analysis compared metabolic and bariatric surgery against GLP-1 receptor agonists. Why the comparison is harder than it looks.
- Does Amylin Need a GLP-1 Partner?CagriSema pairs amylin with semaglutide and missed non-inferiority. A 2026 review surveys long-acting amylin peptides being developed on their own.
- The Trial Where Glucose-Dependence Shows Up in Numbers2,002 randomised, 52 weeks. Hypoglycaemia 6-9% with tirzepatide against 19% with glargine - and 1-3% versus 16% without a sulfonylurea.